IL1RL1 and kidney disorder: In the attempt to translate this concept into a therapeutic approach for potential use in human renal disease, a novel hybrid cytokine linking IL-33 with IL-2 has been designed to activate cell types that express a combination of the respective receptors, such as ST2+CD25+ Tregs and ST2+CD25+ ILC2s.